(Q41637423)

5 October 2017

More Than 7 Years of Hindsight: Revisiting the FDA's 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications (English)

1 reference

5 October 2017

1 reference

Emily E Regier

1

1 reference

PMCID

5070965

5 October 2017

Manu V Venkat

series ordinal

2

1 reference

PMCID

5070965

5 October 2017

Kelly L Close

series ordinal

3

1 reference

5 October 2017

1 October 2016

1 reference

5 October 2017

1 reference

5 October 2017

34

1 reference

5 October 2017

4

1 reference

5 October 2017

173-180

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

5 October 2017

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Economic costs of diabetes in the U.S. in 2012

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

10-year follow-up of intensive glucose control in type 2 diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070965

6 October 2017

Identifiers

DOI

10.2337/CD16-0005

1 reference

5 October 2017

1 reference

5 October 2017

1 reference

PMCID

5070965